<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645150</url>
  </required_header>
  <id_info>
    <org_study_id>S-154/2012</org_study_id>
    <nct_id>NCT01645150</nct_id>
  </id_info>
  <brief_title>Reduction of Cancer Related Fatigue in Patients During TKI Therapy</brief_title>
  <acronym>RECAP</acronym>
  <official_title>Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Cancer Patients During Tyrosine Kinase Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine the effects of a 12-week resistance training
      program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor
      (TKI) therapy. It is hypothesized that incidence and severity of cancer related fatigue can
      be reduced by exercise training in this population which leads to an improved treatment
      completion rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cancer related fatigue</measure>
    <time_frame>From baseline to the 6th and 12th week of training.</time_frame>
    <description>Assessed via the Multidimensional Fatigue Inventory (MFI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength of the knee extensor, hip flexor and forearm flexor muscles.</measure>
    <time_frame>From baseline to the 12th week of training.</time_frame>
    <description>Assessed isokinetically and isometrically via an IsoMed2000 test system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endurance capacity</measure>
    <time_frame>From baseline to the 12th week of training.</time_frame>
    <description>Maximal oxygen uptake (VO2max) assessed in a maximal incremental cycling test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition</measure>
    <time_frame>From baseline to the 12th week of training</time_frame>
    <description>Assessed via bio-impedance measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>From baseline to the 6th and 12th week of training.</time_frame>
    <description>Assessed via the EORTC QLQ C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression</measure>
    <time_frame>From baseline to the 6th and 12th week of training.</time_frame>
    <description>Assessed via &quot;Allgemeine Depressionsskala&quot; (ADS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the first tumor progression under TKI therapy</measure>
    <time_frame>Within the first 6 months of TKI therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of reduction or replacement of TKI therapy</measure>
    <time_frame>Within the first 6 months of TKI therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>All Tumor Entities Treated With TKI Therapy</condition>
  <arm_group>
    <arm_group_label>Strength training group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of progressive strength training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Progressive strength training</intervention_name>
    <description>12 weeks of supervised progressive strength training</description>
    <arm_group_label>Strength training group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female cancer patients

          -  Prior to tyrosine kinase inhibitor therapy (any substance, any line)

          -  Age: at least 18 yrs

          -  Body mass index (BMI): at least 18 kg/m2

          -  ECOG performance status: at most 2

          -  Must be able to meet the requirements of the study protocol

        Exclusion Criteria:

          -  Acute infectious diseases

          -  No ambulatory ability

          -  Severe neurological disorders

          -  Severe cardiovascular diseases

          -  Severe pulmonary insufficiency

          -  Severe renal insufficiency

          -  Other current tumor diseases

          -  Conditions rendering compliance impossible

          -  Participation in regular strength training
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Grüllich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friederike Scharhag-Rosenberger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Wiskamann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Jäger, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Steindorf, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tumor Diseases Heidelberg (German Cancer Research Center/University Hospital Heidelberg)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>physical activity</keyword>
  <keyword>exercise</keyword>
  <keyword>training</keyword>
  <keyword>fatigue</keyword>
  <keyword>cancer</keyword>
  <keyword>TKI</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

